Under the background of continuous improvement of the pharmaceutical innovation environment, increasing investment in research and development funds, rapid expansion of innovative drug pipelines, and accelerated launch of new drugs, the application of digitalization has gradually begun to become a hot spot
for technological innovation in the industry.
In recent years, the pharmaceutical industry has blown the wind
of "digital" transformation.
For example, in the 2022 semi-annual report, Yunnan Baiyao introduced six major performance drivers, including "digital +: keep up with the innovation trend of the pharmaceutical industry and use digital intelligence technology to promote the development of the company"
.
Under the empowerment of digital, pharmaceutical companies are blowing the wind of transformation (Source: Pharmaceutical Network)
Yunnan Baiyao said that considering the company's own resource endowments and cutting-edge technologies in the industry, the company will carry out medium- and long-term layout: digitalization and artificial intelligence
.
Among them, in terms of digitalization, the group-level digital interconnection and process system solidification will be completed, and the business information barriers will be penetrated to achieve business digitization and operation systematization
.
In terms of artificial intelligence, we will explore innovative technologies led by AI and big data to help enterprises to revolutionize agile and empower
key businesses such as research and development, production, marketing, and customer service.
It is reported that on July 23, Yunnan Baiyao and Huawei Technologies Co.
, Ltd.
also signed the "Comprehensive Cooperation Agreement on Artificial Intelligence Drug Research and Development" in Fuzhou City, Fujian Province, aiming to jointly promote the deep integration
of artificial intelligence technology and the big health industry market.
With the development and gradual rise of 5G technology, Dong'e Ejiao also determined the transformation strategy
of "transforming to digital marketing and social new retail platform" before the epidemic in 2019.
Recently, Dong'e Ejiao released the first half of the year results and also announced, net profit increased by 106%
year-on-year.
For the reason for the growth of performance, it is clear that the company closely follows the strategic main line with consumer demand as the core, continuously optimizes the product structure, and upgrades the product portfolio; In-depth practice of customer-centric digital operation model, deepen category extension and innovation exploration, to achieve customer growth and performance improvement
.
In addition to domestic pharmaceutical companies, multinational pharmaceutical companies have also made frequent
moves in digital layout.
In March this year, Merck underwent a restructuring in China, creating two new roles of Data Protection Officer and Chief Transformation Officer, and merging Digital Engagement with Transformation and Commercial Operations to create a new Business Excellence division, and merging Business Operations and Key Account Management to create a new Business Excellence division
.
In June, AstraZeneca announced new structural adjustments and established a new CCiC innovation management team, which was officially implemented
on July 1.
The adjustment of AstraZeneca's CCiC innovative disease management team in China is also considered by the industry to be its in-depth layout
towards digital innovation and development.
It is worth mentioning that at present, in the context of the vigorous development of digitalization by pharmaceutical companies, domestic CRO head enterprises are also using informatization and big data to empower all aspects of drug research and development, including reducing research and development costs, helping pharmaceutical companies improve research and development efficiency, shortening the research and development cycle, and accelerating the process of
drug marketing.
Some reports point out that the domestic digital CRO industry is developing rapidly, and it is expected that the incremental market of the industry in the future will be more than 3 times that of
the existing market.
On the whole, digitalization has become a trend
in the development of the pharmaceutical industry.
So, with the blessing of digitalization and intelligence, can pharmaceutical companies usher in new market increments? In this regard, the industry believes that digitalization has brought new technical means and development opportunities for pharmaceutical research and sales, which can effectively improve the efficiency of innovative drug development and increase sales channels and methods
.
However, domestic digitalization + medicine is still in the initial stage, and it takes a long time to run in and trial and error
.
Therefore, the current enterprises to increase the layout of "digitalization", which can be regarded as a future plan, but it is difficult to improve the status quo
of pharmaceutical companies in a short period of time.
However, in general, the digital development trend of pharmaceutical companies to increase the layout will not change
.
It is understood that on August 30, the Ministry of Industry and Information Technology held a press conference, and the relevant person in charge introduced at the press conference that it will build a digital policy system, support system and empowerment system for small and medium-sized enterprises, and comprehensively promote the acceleration, expansion, quality improvement and efficiency
of the digital transformation of small and medium-sized enterprises.
Affected by this, the industry expects that in the future, more and more pharmaceutical companies will begin to use artificial intelligence, big data, electronic data collection and other technologies and platforms to accelerate the efficiency of drug research and development, further promote the process of clinical trials, and close the relationship with
doctors and patients.
